Immunotherapy of cancer by IL-12-based cytokine combinations

Jonathan M. Weiss(Max Planck Institute for Metabolism Research), Robert H. Wiltrout(Frederick National Laboratory for Cancer Research), Jeffrey Subleski(National Cancer Institute), Jon M. Wigginton(Bristol-Myers Squibb (United States))
Expert Opinion on Biological Therapy
October 26, 2007
10.1517/14712598.7.11.1705
Cited by 223

Related Papers

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k
Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2015|1.2k